Bicycle Therapeutics appoints Andy Sandham as non-executive Chairman

07-Jan-2011 - United Kingdom

Bicycle Therapeutics announced the appointment of Andy Sandham as non-executive Chairman.  Andy brings over 30 years experience in building biotechnology businesses.  He will work closely with founders, Sir Gregory Winter, FRS and Christian Heinis, and CEO, Dr John Tite, to drive the discovery and development of a new generation of biotherapeutics using the company’s proprietary bicyclic peptide technology. In addition to Andy’s appointment, Bruce Booth will be joining the Board to replace Regina Hodits as the Atlas Venture representative director.

Andy Sandham has played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceuticals. He has also served as non-executive chairman of Syntaxin, Novacta Biosystems, non-executive director of Synosia and was a venture partner with Abingworth LLP.  Andy is currently also Chairman and CEO of Kymab and is a non-executive director of NeurAxon and  PBL.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances